For decades, Sialkot has been the backbone of a global surgical instruments supply chain. When a surgeon in Germany or France picks up a pair of forceps or a retractor, chances are high it was forged, ground, and polished in our city.

But the regulatory landscape in Europe has changed fundamentally. The EU Medical Device Regulation (MDR) 2017/745 is no longer a future deadline — it is fully applicable. And for Pakistani manufacturers, this is not just a paperwork exercise. It is a fundamental shift in how we must prove quality, traceability, and safety.

What has changed under MDR?

Under the old MDD (Medical Devices Directive), a Sialkot manufacturer of non-sterile, Class I instruments (like basic scalpels or scissors) could largely self-certify. The responsibility sat mainly with the European importer. Under MDR, that is gone. Even for Class I instruments, the scrutiny has increased. You now need:

• More detailed technical documentation — not just a catalogue, but full design and manufacturing process files.
• A robust Quality Management System (QMS) — typically certified to ISO 13485:2016, which is now the baseline.
• Clinical evaluation reports — even for basic instruments, you must show evidence of safety and performance.
• Post-market surveillance (PMS) — a proactive plan to monitor how your instruments perform once they are in the field.

For instruments that are sterile or have a measuring function, the requirements are even higher, involving Notified Body approval.

What Sialkot suppliers must demonstrate today

If you are exporting to the EU, your buyers will likely ask for three clear things.

What European buyers should be asking for

To colleagues in Europe who are sourcing from Sialkot: do not assume your long-term supplier understands MDR fully. Ask specific questions:

• Request their ISO 13485 certificate and verify its scope against what they are supplying you.
• Ask for a copy of their technical file for a sample instrument.
• Request their post-market surveillance report — even a basic one.
• Confirm who their EU Authorised Representative is, and get the contract details.

If your Sialkot supplier cannot produce these, they are not compliant — and you are carrying the legal risk.

The practical reality for Sialkot

Many manufacturers here feel this is heavy bureaucracy. In some ways, it is. But it also creates a real opportunity. The middle-tier suppliers who treat MDR as a one-time paperwork exercise will struggle. The serious ones who integrate quality and documentation into their daily production will gain trust — and long-term European contracts.

Several leading local manufacturers have already invested in new cleanrooms, digital traceability systems, and dedicated regulatory staff. They are now preferred suppliers for top European distributors. The message is clear: MDR compliance is no longer optional — it is the price of market access.

After 16 years working inside the Sialkot surgical cluster, I have watched overseas buyers make the same mistakes again and again. They focus on price and samples, but miss the early warning signs that a supplier will eventually fail — on quality, on delivery, or on compliance.

Here are five red flags I have learned to spot. If you see even two of them, walk away.

Sialkot has excellent, world-class suppliers. But it also has traders posing as manufacturers, and workshops still operating like it is 1995. The red flags above are not about being difficult. They are about protecting your brand, your patients, and your supply chain.

I have lost count of how many European buyers have told me, “We visited the factory ourselves — everything looked fine.” And then, six months later, those same buyers received a container of instruments with inconsistent hardness, wrong steel grades, or missing paperwork.

Here is the uncomfortable truth: walking through a workshop and shaking hands with the owner is not an audit. It is a visit. And a visit tells you very little about a supplier’s real quality systems, traceability, or regulatory readiness.

What a “visit” typically includes

A standard buyer visit to a Sialkot supplier usually looks like this: a tour of the production floor (often cleaned up beforehand), a look at finished samples, a friendly meeting over tea, and a verbal assurance that “quality is our priority.” None of this is useless — it builds relationships. But it does not verify systems. It does not uncover hidden risks. And it will never satisfy the due diligence requirements of EU MDR or FDA regulations.

What a qualified audit includes

An audit conducted by a trained auditor goes much deeper. Here is what actually happens:

Why the difference matters

If you rely on a friendly visit, you accept three serious risks. First, regulatory risk: under EU MDR, you as the importer are legally responsible for your supplier’s compliance. If you cannot show documented audit evidence, your Notified Body will reject your technical file. Second, batch-to-batch inconsistency: without a documented quality system, a supplier might produce perfect samples but fail on a large order when pressure increases. Third, hidden sub-suppliers: many Sialkot manufacturers outsource heat treatment, laser marking, or passivation to smaller workshops. A visit often misses this completely.

What you should do

• Separate relationship visits from compliance audits. Do both, but know which is which.
• If you cannot send a trained auditor yourself, hire a reputable third-party based in Sialkot.
• Use a structured audit checklist based on ISO 13485 clauses — grade each requirement as compliant, partially compliant, or non-compliant.
• Insist on seeing objective evidence — documents, not words.
• Schedule regular yearly or bi-yearly follow-up audits, not one-time events.

One question I hear from nearly every overseas buyer is: “Am I paying the right price?” It is a fair question. The Sialkot surgical instrument market is not transparent like an online commodity exchange. Prices vary by supplier, by grade, by volume, and even by season.

After nearly two decades here, I have learned that fair pricing is not about finding the cheapest quote. It is about understanding what drives costs and where the hidden traps lie.

The main cost drivers

Where buyers commonly overpay

Through years of helping buyers audit suppliers, I have seen three recurring overpayment patterns.

The trader markup. You contact a company with a professional website and English-speaking staff. They take your order and send it to a small workshop down the road, adding 25–40% without telling you. You never meet the actual manufacturer. The solution? Ask directly: “Do you own the production floor? May I see a video of your forging and grinding area?” Traders hesitate. Manufacturers show you.

Vague “premium” claims. A supplier says “We use German steel” and charges double. When you ask for the mill certificate, they cannot produce it. Fair pricing requires proof. Never accept a premium charge without documented evidence.

Unnecessary over-engineering. Some workshops will convince you that every instrument needs full electropolishing and individual laser etching — even for disposable or low-use items. Ask yourself: is this instrument for high-volume single use or for reusable surgery? Match the specification to the application.

How to benchmark a fair price

• Get three quotes from different Sialkot suppliers for the exact same specification — same steel, same finish, same packaging.
• Throw out the lowest and the highest. The middle is likely the market rate.
• Ask each supplier to break down the quote into material, labour, finishing, and packaging. The ones who cannot or will not are hiding something.
• Compare against a reference from an existing supplier or ask a reputable local sourcing agent for a ballpark range.

If you are a European buyer sourcing surgical instruments from Pakistan, you have likely seen the term EC-REP or “Authorised Representative” in your compliance documents. But many buyers do not fully understand what an EC-REP does — and more importantly, who is responsible if something goes wrong.

What is an EC-REP?

Under EU MDR 2017/745, any medical device manufacturer located outside the European Union must designate a natural or legal person within the EU as their Authorised Representative — commonly called EC-REP. This representative is not a distributor. They do not sell products. Their role is to act as the EU-facing point of contact for regulatory compliance, and their name and address must appear on the device labelling or packaging.

In simple terms: if you are a Pakistani manufacturer, you cannot sell directly into the EU market without an EC-REP. And if you are a European buyer, your supplier must have one — or you may become the de facto manufacturer by default.

What does an EC-REP actually do?

• Register the non-EU manufacturer in the EUDAMED database.
• Verify that the manufacturer has prepared the required technical documentation and Declaration of Conformity.
• Keep those documents available for inspection by competent authorities for at least 10 years.
• Cooperate with authorities on any corrective actions, recalls, or vigilance reports.
• Act as the legal recipient for any requests or complaints from EU regulators.

Common misunderstandings — and risks

What European buyers should ask their Pakistani suppliers

Before you place your next order, ask these three questions:

1. “Do you have a signed, active EC-REP agreement? Please share the name, address, and contract validity date.”
2. “Which Notified Body is associated with your EC-REP (if any)?”
3. “May I contact the EC-REP directly to confirm they hold your current technical documentation?”

If your supplier hesitates or says “Our agent in Europe handles everything” without details, that is a serious red flag.

Practical recommendations

• Do not accept a verbal assurance. Request a copy of the EC-REP contract to confirm it is in place.
• Verify the EC-REP is not simply a freight forwarder or trading office — they must have regulatory expertise.
• If your supplier has no EC-REP, help them appoint one. Reputable firms like Obelis, Qarad, or LNE-GMED are known in the industry. Cost is typically EUR 3,000–6,000 annually.
• Document everything — your technical file must include the EC-REP name and address exactly as it appears on the label.

For more than ten years, I served as the on-ground agent for a French surgical instruments importer. They relied on me to find reliable Sialkot suppliers, inspect quality, resolve disputes, and ensure containers shipped on time. It was an intense education — one that taught me more about international sourcing than any textbook or training course ever could.

Looking back, a few lessons stand out. These are the truths I now carry into every buying relationship.

There is a structural compliance gap in Pakistan’s surgical instruments export sector. Many manufacturers in the Sialkot cluster are aware that EU MDR 2017/745 changed something significant about how they must operate. Fewer are aware of the specific legal obligations that apply to them as of May 28, 2026 — and fewer still have taken the steps required to remain in legal compliance.

This article explains those obligations with precision: what the PRRC is, who qualifies to serve in that role, why geography matters more than many assume, and what the two binding EUDAMED deadlines mean for existing and new device registrations.

Section 01 — What is a PRRC and Who Qualifies?

Article 15 of EU MDR 2017/745 requires every medical device manufacturer to have at least one Person Responsible for Regulatory Compliance (PRRC). This is a named individual — not a company, not a department — who carries personal legal responsibility for ensuring that:

• Devices are manufactured and released in conformity with the MDR
• Technical documentation and the Declaration of Conformity are prepared and kept up to date
• Post-market surveillance, vigilance reporting and FSCA obligations are met
• Batch release is conducted in accordance with Article 10(8)
• Registration obligations, including EUDAMED, are fulfilled

The PRRC is not an administrative title. It carries regulatory weight. Under Article 15(5), the PRRC must not be penalised by the manufacturer for performing these duties in good faith — language that signals the EU legislature’s intention that this person operate with genuine independence.

Section 02 — The "Close Linkage" Principle: Why Pakistan-Based Matters

One of the most practically significant — and frequently misunderstood — aspects of the PRRC requirement concerns geography.

This means that for Sialkot and Faisalabad manufacturers, a Pakistan-based PRRC is the regulatory expectation — not a preference. A consultant based in Germany, France, or the Netherlands cannot satisfy this “close linkage” requirement on your behalf as manufacturer-PRRC, however qualified they may otherwise be.

There is a further important distinction: the PRRC of the manufacturer and the PRRC of the EU Authorized Representative (AR) must be two different persons, from different organisations. Your manufacturer-side PRRC appointment is a distinct obligation from your AR’s compliance structure.

Section 03 — The Micro and Small Enterprise Advantage

The majority of Pakistani surgical instrument manufacturers — particularly family-owned and SME-scale factories in the Sialkot cluster — qualify as Micro or Small Enterprises under the EU definition: fewer than 50 employees and annual turnover or balance sheet total below €10 million.

Under Article 15(2) of the MDR, these companies are not required to employ a PRRC as a full-time, salaried member of staff. Instead, they may engage an external consultant under a formal service contract — provided that person is “permanently and continuously at their disposal.”

Section 04 — Two Critical EUDAMED Deadlines

The May 28, 2026 date has received most of the industry attention — but it is only one of two binding deadlines. Every Pakistani manufacturer with EU export intentions must understand both:

Both deadlines are activated by Commission Decision (EU) 2025/2371, published November 27, 2025 in the Official Journal of the European Union. This is no longer a grace period — it is an elapsed one.

Section 05 — The December 2025 Reform Proposal: What It Actually Changes

On December 16, 2025, the European Commission published its legislative proposal COM(2025) 1023 to amend the MDR and IVDR. As of May 2026, it is under evaluation by the European Parliament and Council and has not yet entered into force.

Section 06 — What Pakistani Manufacturers Must Do Now

The Pakistani surgical instruments industry has served European operating theatres for decades. The manufacturers who will continue to do so are those who treat regulatory compliance not as administrative overhead, but as a market access investment — one that protects existing buyer relationships and opens doors to new ones.

The PRRC mandate, properly implemented, is precisely that investment.